☰

Karl J. Erlandson, Ph.D. - Publications

Affiliations: 
2009 Harvard University, Cambridge, MA, United States 
Area:
Endoplasmic Reticulum, Secretion
Tree Info Grants Similar researchers PubMed Report error

7/20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Erlandson KJ, Bisht H, Weisberg AS, Hyun SI, Hansen BT, Fischer ER, Hinshaw JE, Moss B. Poxviruses Encode a Reticulon-Like Protein that Promotes Membrane Curvature. Cell Reports. PMID 26923595 DOI: 10.1016/J.Celrep.2016.01.075  0.407
2014 Erlandson KJ, Cotter CA, Charity JC, Martens C, Fischer ER, Ricklefs SM, Porcella SF, Moss B. Duplication of the A17L locus of vaccinia virus provides an alternate route to rifampin resistance. Journal of Virology. 88: 11576-85. PMID 25078687 DOI: 10.1128/Jvi.00618-14  0.323
2008 Erlandson KJ, Miller SB, Nam Y, Osborne AR, Zimmer J, Rapoport TA. A role for the two-helix finger of the SecA ATPase in protein translocation. Nature. 455: 984-7. PMID 18923526 DOI: 10.1038/Nature07439  0.622
2008 Erlandson KJ, Or E, Osborne AR, Rapoport TA. Analysis of polypeptide movement in the SecY channel during SecA-mediated protein translocation. The Journal of Biological Chemistry. 283: 15709-15. PMID 18359943 DOI: 10.1074/Jbc.M710356200  0.711
2007 Li W, Schulman S, Boyd D, Erlandson K, Beckwith J, Rapoport TA. The plug domain of the SecY protein stabilizes the closed state of the translocation channel and maintains a membrane seal. Molecular Cell. 26: 511-21. PMID 17531810 DOI: 10.1016/J.Molcel.2007.05.002  0.695
2007 Saparov SM, Erlandson K, Cannon K, Schaletzky J, Schulman S, Rapoport TA, Pohl P. Determining the conductance of the SecY protein translocation channel for small molecules. Molecular Cell. 26: 501-9. PMID 17531809 DOI: 10.1016/J.Molcel.2007.03.022  0.704
2004 Plemper RK, Erlandson KJ, Lakdawala AS, Sun A, Prussia A, Boonsombat J, Aki-Sener E, Yalcin I, Yildiz I, Temiz-Arpaci O, Tekiner B, Liotta DC, Snyder JP, Compans RW. A target site for template-based design of measles virus entry inhibitors Proceedings of the National Academy of Sciences of the United States of America. 101: 5628-5633. PMID 15056763 DOI: 10.1073/Pnas.0308520101  0.319
Low-probability matches (unlikely to be authored by this person)
2016 Mendez-Rios JD, Yang Z, Erlandson KJ, Cohen JI, Martens CA, Bruno DP, Porcella SF, Moss B. Molluscum Contagiosum Virus Transcriptome in Abortively Infected Cultured Cells and Human Skin Lesion. Journal of Virology. PMID 26889040 DOI: 10.1128/Jvi.02911-15  0.221
2018 Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, ... ... Erlandson K, et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in non-human primates. The Journal of Infectious Diseases. PMID 29860496 DOI: 10.1093/Infdis/Jiy285  0.208
2016 Uyeki TM, Erlandson K, Korch G, O'Hara M, Wathen M, Hu-Primmer J, Hojvat S, Stemmy EJ, Donabedian A. Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus. Emerging Infectious Diseases. 22. PMID 27191188 DOI: 10.3201/Eid2207.160022  0.207
2016 Marjuki H, Mishin VP, Chai N, Tan MW, Newton EM, Tegeris J, Erlandson K, Willis M, Jones J, Davis T, Stevens J, Gubareva LV. Human monoclonal antibody 81.39a effectively neutralizes emerging influenza A viruses of group 1 and 2 hemagglutinins. Journal of Virology. PMID 27630240 DOI: 10.1128/Jvi.01284-16  0.206
2018 de Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, Scott D, Erlandson KJ, Stahl N, Lipsich L, Kyratsous CA, Feldmann H. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Research. PMID 29885377 DOI: 10.1016/J.Antiviral.2018.06.006  0.204
2021 Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD. Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. Journal of Virology. JVI0111021. PMID 34668774 DOI: 10.1128/JVI.01110-21  0.149
2021 Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity. Biorxiv : the Preprint Server For Biology. PMID 34790980 DOI: 10.1101/2021.11.05.467523  0.099
2021 Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses. 13. PMID 34960755 DOI: 10.3390/v13122485  0.089
2022 Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, ... ... Erlandson KJ, et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. Science Translational Medicine. eabn8543. PMID 35380448 DOI: 10.1126/scitranslmed.abn8543  0.077
2001 Alavi M, Miller T, Erlandson K, Schneider R, Belas R. Bacterial community associated with Pfiesteria-like dinoflagellate cultures Environmental Microbiology. 3: 380-396. PMID 11472503 DOI: 10.1046/J.1462-2920.2001.00207.X  0.073
2021 Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, ... ... Erlandson KJ, et al. SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. Biorxiv : the Preprint Server For Biology. PMID 34981057 DOI: 10.1101/2021.12.22.473880  0.053
2023 Ambrose N, Amin A, Anderson B, Barrera-Oro J, Bertagnolli M, Campion F, Chow D, Danan R, D'Arinzo L, Drews A, Erlandson K, Fitzgerald K, Garcia M, Gaspar FW, Gong C, et al. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes. Jama Network Open. 6: e239694. PMID 37093599 DOI: 10.1001/jamanetworkopen.2023.9694  0.041
2023 Ambrose N, Amin A, Anderson B, Bertagnolli M, Campion F, Chow D, Danan R, D'Arinzo L, Drews A, Erlandson K, Fitzgerald K, Gaspar F, Gong C, Hanna G, Hawley H, et al. The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19. Journal of General Internal Medicine. PMID 37715096 DOI: 10.1007/s11606-023-08324-y  0.036
Hide low-probability matches.